US EditionMabwell signs Albipagrastim alfa deal with Qilu Pharmaceutical
Summary by Pharmaceutical Business Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Mabwell signs Albipagrastim alfa deal with Qilu Pharmaceutical
This agreement grants Qilu exclusive rights to develop, manufacture, enhance, utilise and commercialise Albipagrastim alfa for Injection in Greater China including Chinese Mainland, Macau, Hong Kong and Taiwan. The post Mabwell signs Albipagrastim alfa deal with Qilu Pharmaceutical appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
